ClinicalTrials.gg
Active, not recruitingNCT06485596HOPE@HeartUpdated Aug 3, 2026

HOPE at Heart (HOPE) of Donor Hearts After Circulatory Death (DCD) Using the XVIVO Heart Assist Transport System.

An interventional study of XVIVO Heart Assist Transport System in Heart Failure, sponsored by XVIVO Perfusion. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by XVIVO Perfusion · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Heart Failure with a site in Netherlands — 57 open to participants now, 80 under way, 13 of them phase 3. Heart Failure · Netherlands.

Enrollment
192nd of 234
40 · median 284
Started
2024
with 19 others
No phase
105 of 313
19 open now
Primary completion
2026-08
later than 24 of 79 live
Registered
273rd of 313
by date

Among the 313 studies in Heart Failure with a site in Netherlands, this one is the 192nd largest by enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2024, is one of 105 with no phase, reaches primary completion later than 24 of the 79 other live ones, and was the 273rd registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

57 of the 313 studies in Heart Failure with a site in Netherlands are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Heart Failure with a site in Netherlands, or all of them as a file.
02

Study summary

The purpose of the clinical investigation is to support the use of direct procurement of donor hearts in donation after circulatory death followed by hypothermic oxygenated perfusion using the XVIVO Heart Assist Transport System. Thereby increasing the utilization of DCD donor hearts in donation after circulatory death.

The primary objective is to evaluate patient survival after direct procurement and hypothermic oxygenated machine perfusion of DCD donor hearts using the XVIVO Heart Assist Transport System.

The secondary objectives are to evaluate patient outcomes and graft function post-transplant.

Read the detailed description

This is a prospective, single-arm, multi-national, multicentre, proof-of-concept study to evaluate post-transplant outcomes after the use of direct procurement followed by a period of hypothermic oxygenated perfusion of the donor heart in DCD using the XVIVO Heart Assist Transport system.

The investigation will be conducted at 4 heart transplant centres, one in Belgium and three in The Netherlands.The study will include 40 DCD heart transplant recipients and will evaluate transplant outcomes such as post-transplant complications, patient survival and graft function for a period of 6 months post-transplant.

The study will not include a control group as this is a proof-of-concept study, investigating an alternative method of procurement of DCD hearts by providing additional safety and performance data.

The primary objective is to evaluate patient survival after direct procurement and hypothermic oxygenated machine perfusion of DCD donor hearts using the XVIVO Heart Assist Transport System.

The secondary objectives are to evaluate patient outcomes and graft function post-transplant.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Recipient Criteria:

  1. Age ≥18 years
  2. Signed form
  3. Accepted and/or listed for heart transplantation

Exclusion Recipient Criteria:

  1. Not able to understand the information provided during the informed consent procedure
  2. Previous solid organ transplantation
  3. Grown-up congenital heart disease
  4. Dialysis
  5. Incompatible blood group
  6. Combined organ transplantation candidates
  7. Subjects under pre-transplant desensitization protocol (including plasma exchange in conjunction with the transplant surgery)
  8. Mechanical circulatory support pre-transplantation (except durable Left ventricular assist device or Intra-aortic balloon pump)

Inclusion - Heart donor

  1. Accepted as a heart donor by the transplant team based on current standard of care criteria
  2. DCD Maastricht category III and euthanasia donors
  3. Age ≤ 60 years old

Exclusion - Heart Donor

  1. Functional warm ischemia time (FWIT) > 30 minutes.
  2. Donor cardiac arrest does not occur within 120 minutes from Withdrawal of life sustaining therapy (WLST)
  3. Deviations from Donor end of life treatment protocol as defined by local standard operating procedures
  4. Donor heart assessed as not transplantable by the responsible clinician at any time point during the donation or procurement procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    DCD Direct procurement

    Direct procurement of DCD donor hearts

    Device: XVIVO Heart Assist Transport System

Interventions

  • DeviceXVIVO Heart Assist Transport System

    Direct procurement of donor hearts from DCD donation

    Also known as: Direct procurement

06

What researchers measure

Primary outcomes

  1. Patient survival

    Time frame: 30 days post-transplant

Secondary outcomes

  1. Cardiac related mortality

    Time frame: 30 days post-transplant

  2. Incidence of Mechanical circulatory support

    Time frame: 30 days post-transplant

  3. Incidence of severe Primary Graft Dysfunction (PGD) at 24 hours post-transplant (Kobashigawa et al., 2014)

    Time frame: 30 days post-transplant

  4. Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 24 hours and 30 days post-transplant

    Time frame: 30 days post-transplant

  5. Incidence of perfused hearts which are not used for transplantation

    Time frame: 30 days post-transplant

  6. Total duration of ICU stay (days)

    Time frame: 30 days post-transplant

  7. Incidence of biopsy proven rejections > 1 ACR (leading to changed immunosuppressive regime)

    Time frame: 30 days post-transplant

  8. Cardiac related mortality at 6 months post-transplant

    Time frame: 6 months post-transplant

  9. Cardiac function as assessed by left ventricular ejection fraction (LVEF)

    Time frame: 6 months post-transplant

  10. Number of days until hospital discharge from index procedure

    Time frame: 30 days post-transplant

  11. Incidence of biopsy proven rejections > 1 ACR (leading to changed immunosuppressive regime)

    Time frame: 6 months post-transplant

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2026, 24 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 24 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 3, 2024
StartActual
Aug 3, 2024
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06485596
Lead sponsor
XVIVO Perfusion
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Aug 3, 2024
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Aug 3, 2026

Study contacts

Filip Rega, MD, PhD
principal investigator · UZ Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion